Koneksa has teamed up with Beacon Biosignals for a clinical trial to assess the integration of the latter’s at-home electroencephalogram (EEG) into its Neuroscience Solution Toolkit.
The Beacon Platform unlocks longitudinal EEG technology and leverages machine-learning algorithms to increase insights into brain activity, helping sponsors to gain comprehensive data analysis and data visualisation capabilities.
Go deeper with GlobalData
Referred to as LEARNS, the Koneksa-sponsored, syndicated and observational study has been designed for identifying biomarkers and determining the validity and usability measures of sleep and neurologic disorders collected using smartphones, at-home EEG and wearables.
The trial will compare the Koneksa neuroscience solution and the Beacon Biosignals platform for at-home EEG, with in-clinic polysomnography, in neurological and sleep disorders.
Parkinson’s, Alzheimer’s and Huntington’s, as well as mild cognitive impairment, obstructive sleep apnoea and narcolepsy are the current cohorts in the LEARNS study.
Koneksa chief medical officer John Wagner said: “Beacon’s mobile EEG will join more than a dozen digital health technologies that are already integrated into the Koneksa solution.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe trial will measure the validity of smartphone-based motor, speech and cognitive assessments against gold-standard tools.
Furthermore, it will evaluate whether assessment combinations hold the potential to detect diagnostic features at the cohort diagnostic boundary.
Beacon Biosignals co-founder and CEO Dr Jacob Donoghue said: “With our shared science-first ethos, we are united in our relentless pursuit to develop cutting-edge tools that revolutionise drug development and accelerate the delivery of life-changing therapies to patients.”
